2024-06-102024-06-102022Serrano Morales, J.M., Hita Cantalejo, M.C.d., Sánchez González, M.d.C., Bautista Llamas, M.J. y Sánchez González, J.M. (2022). Efficacy of 0.1% crosslinked hyaluronic acid, coenzyme Q10 and vitamin E in the management of dry eye disease in menopause patients receiving antidepressants. European Journal of Ophthalmology, 32 (1), 658-663. https://doi.org/10.1177/1120672120972026.1724-6016 (electrónico)1120-6721 (impreso)https://hdl.handle.net/11441/160130Purpose. The purpose of this study is to test non-inferiority of a lower dose of crosslinked hyaluronic acid (CLHA) to a higher dose of carmellose eye drop in menopause patients receiving antidepressant treatments. Methods. This prospective, double-blind, single-center study enrolled sixty female patients. Mean age was 63.25 ± 9.13 years. We examined patients with Schirmer I, breakup time (TBUT) and the ocular surface disease index (OSDI) at the first visit. Tear A eyedrops were formulated with crosslinked hyaluronic acid, coenzyme Q10 and vitamin E. Control tear B was formulated with carmellose sodium. Posology was two and five times, respectively. Results. After two months of treatment, the tear A obtained 14.12 ± 7.47 score points for OSDI (t = 11.74, P < .01), and tear B obtained 19.46 ± 10.03 score points (t = 7.59, P < .01). The tear A obtained 13.77 ± 7.78 score points for Schirmer test (t = 0.88, P > .05), and tear B obtained 14.20 ± 8.62 score points (t = 2.92, P < .01). The tear A obtained 8.30 ± 2.08 seconds for TBUT (t = 15.50, P < .01), and tear B obtained 7.23 ± 2.40 seconds (t = 8.79, P < .01). Conclusions. Lower total daily dose of crosslinked hyaluronic acid eyedrops obtained similar efficacy results in terms of tear stability and subjective dry eye sensation than higher carmellose total daily dose. A lower total daily dose of crosslinked eyedrops was sufficient to achieve better dry eye disease management compared to carmellose.application/pdf18 p.engCrosslinked hyaluronic acidCoenzyme Q10Dry eyeEyedropsAntidepressantEfficacy of 0.1% crosslinked hyaluronic acid, coenzyme Q10 and vitamin E in the management of dry eye disease in menopause patients receiving antidepressantsinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccesshttps://doi.org/10.1177/1120672120972026